MCT Enteral Feeding to Reduce Chyle Leak After Oesophagectomy
Recruiting
N/A
Interventional Study
Oesphageal Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 160 (estimated)
- Sponsor
- Royal College of Surgeons, Ireland · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Chyle leak (chylothorax) is a recognised complication following minimally invasive oesophagectomy for oesophageal cancer and may result in prolonged hospital stay, nutritional compromise, and need for additional interventions.
Medium-chain triglyceride (MCT) feeds reduce lymphatic flow as they are absorbed directly via the portal circulation rather than through the thoracic duct. While MCT feeds …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age ≥ 18 years
* Diagnosis of oesophageal cancer (adenocarcinoma or squamous cell carcinoma)
* Planned minimally invasive or robotic-assisted oesophagectomy (MIO or RAMIO) with curative intent
* Placement of feeding jejunostomy at or prior to oesophagectomy
* Able to provide w…
Contacts